ASND Share Price Performance

US$263.52

18.13 (7.39%)

US$313.36

Fair Value

US$263.52

18.13 (7.39%)

15.9% undervalued

US$313.36

Fair Value

US$263.52

US$313.36

US$269.41

Fri, 21 Aug 26

Fair ValueUS$313.36

Share Pricen/a

ASND Community Narratives

AnalystConsensusTarget's

Fair Value

Fair Value US$313.36 15.9% undervalued

Long Acting TransCon Therapies Will Reshape Rare Endocrine Treatment Over The Coming Years

AnalystLowTarget's

Fair Value

Fair Value US$269.41 2.2% undervalued

Long Term TransCon Pipeline Execution Will Shape Future Cash Flows And Business Durability

About ASND

Founded: 2006
Employees: 1189
CEO: Jan Mikkelsen
WebsiteView website: ascendispharma.com

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Recent ASND News & Updates

Announcement • Sep 10

Ascendis Pharma Presents Week 52 Data from Reachin Trial of Once-Weekly Transcon Cnp (Navepegritide) in Infants with Achondroplasia

Ascendis Pharma A/S announced Week 52 data from the open-label sentinel cohort portion of the reACHin Trial showing that treatment with once-weekly TransCon CNP (navepegritide) provided stabilization or improvement in foramen magnum stenosis, as well as linear growth benefits, in infants with achondroplasia. Treatment with TransCon CNP led to stable or improved cranio-cervical junction health at Week 52, as measured by: AFMS was stable or improved between baseline and Week 52 in all children. Mean change from baseline in sagittal diameter of foramen magnum was +3.15 mm. There were no decompression surgeries during the 52-week period. Treatment with TransCon CNP increased linear growth at Week 52: Mean change from baseline in ACH-specific supine length Z-score was +0.42. Mean AGV was 9.9 cm/year. PK was comparable to that observed in older children, supporting the 100 µg/kg/week dose. TransCon CNP was generally well tolerated and the safety data were consistent with those previously reported in other trials: No reports of injection site reactions over the 52-week treatment period. No deaths, fractures, bone-related safety events, or symptomatic hypotension. No AEs were assessed by investigators as related to treatment and no AEs led to treatment disruption or discontinuation or to trial withdrawal. TransCon CNP is a prodrug of C-type natriuretic peptide (CNP) administered once weekly, designed to provide continuous exposure of active CNP to receptors on tissues throughout the body to counteract the overactive FGFR3 signaling in achondroplasia. In February 2026, TransCon CNP was approved by the U.S. Food & Drug Administration under the trade name YUVIWEL to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. Ascendis Pharma’s Marketing Authorisation Application for YUVIWEL is under review by the European Medicines Agency, with a regulatory decision anticipated in the fourth quarter of 2026.

Announcement • Sep 04

Pendopharm Announces Canada’S Drug Agency Recommends Reimbursement of Yorvipath (Palopegteriparatide Injection) with Conditions for Eligible Adults with Chronic Hypoparathyroidism

Pendopharm, a division of Pharmascience Inc., in collaboration with Ascendis Pharma A/S, announced that Canada’s Drug Agency, or CDA-AMC, has recommended that Yorvipath (palopegteriparatide injection) be reimbursed with conditions by participating public drug plans for eligible adults with chronic hypoparathyroidism that are not adequately controlled with conventional therapy. Yorvipath (palopegteriparatide injection) is a parathyroid hormone (PTH) replacement therapy for the treatment of chronic hypoparathyroidism in adults, authorized by Health Canada on January 28, 2026. The CDA-AMC recommendation represents an important step in the Canadian public reimbursement process. The CDA-AMC review considered evidence from the Phase 3 PaTHway clinical trial, which evaluated palopegteriparatide in adults with chronic hypoparathyroidism. Participating federal, provincial, and territorial drug plans will make their own final listing decisions. Conventional therapy generally consists of oral calcium and active vitamin D. Guidelines suggest conventional therapy as first-line; PTH therapy may be considered when conventional therapy is unsatisfactory. For appropriate adults, a PTH replacement therapy may offer a different treatment approach by addressing the underlying hormone deficiency. This recommendation is meaningful for the community because it recognizes the challenges experienced by some people living with chronic hypoparathyroidism and the need for access discussions for eligible patients. For more information about the product, such as contraindications, precautions, adverse effects, drug interactions, dosage and clinical usage conditions, please consult the Product Monograph. We encourage patients to consult their doctor for more information to ensure this treatment right choice for them. Always read and follow the label. This product may not be right for you. YORVIPATH is a registered trademark of Ascendis Pharma Bone Diseases A/S, used under license.

Recent updates

No updates

Ascendis Pharma A/S Stock Price

ASND Share Price Performance

ASND Community Narratives

Long Acting TransCon Therapies Will Reshape Rare Endocrine Treatment Over The Coming Years

Long Term TransCon Pipeline Execution Will Shape Future Cash Flows And Business Durability

Long Term TransCon Pipeline Execution Will Shape Future Cash Flows And Business Durability

Long Acting TransCon Therapies Will Reshape Rare Endocrine Treatment Over The Coming Years

Trending Discussion

Recently Updated Narratives

ASND: Yuviwel Settlement And Q2 TransCon Execution Will Test Fairly Priced Story

ASND: TransCon Platform Execution And Q2 Progress Should Drive Future Upside

Snowflake Analysis

Ascendis Pharma A/S Key Details

About ASND

Recent ASND News & Updates

Ascendis Pharma Presents Week 52 Data from Reachin Trial of Once-Weekly Transcon Cnp (Navepegritide) in Infants with Achondroplasia

ASND: Yuviwel Settlement And Q2 TransCon Execution Will Test Fairly Priced Story

Pendopharm Announces Canada’S Drug Agency Recommends Reimbursement of Yorvipath (Palopegteriparatide Injection) with Conditions for Eligible Adults with Chronic Hypoparathyroidism

Recent updates

Ascendis Pharma A/S Competitors

Vertex Pharmaceuticals

Bristol-Myers Squibb

Regeneron Pharmaceuticals

Moderna